Ticker > Company >

Jagsonpal Pharma share price

Jagsonpal Pharmaceuticals Ltd.

NSE: JAGSNPHARM BSE: 507789 SECTOR: Pharmaceuticals & Drugs  65.68 K   157   17

241.70
-6.90 (-2.78%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 253.6

Today's Low

₹ 239.25

52 Week High

₹ 328.02

52 Week Low

₹ 152.34

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

1610.48 Cr.

Enterprise Value

1462.54 Cr.

No. of Shares

6.66 Cr.

P/E

26.48

P/B

6.42

Face Value

₹ 2

Div. Yield

1.03 %

Book Value (TTM)

₹  37.64

CASH

147.93 Cr.

DEBT

0 Cr.

Promoter Holding

67.65 %

EPS (TTM)

₹  9.13

Sales Growth

-11.83%

ROE

14.02 %

ROCE

17.72%

Profit Growth

-15.94 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-11.83%
3 Year3.55%
5 Year4.58%

Profit Growth

1 Year-15.94%
3 Year9.61%
5 Year25.5%

ROE%

1 Year14.02%
3 Year16.06%
5 Year14.35%

ROCE %

1 Year17.72%
3 Year21.04%
5 Year18.4%

Debt/Equity

0

Price to Cash Flow

45.8

Interest Cover Ratio

37.6941

CFO/PAT (5 Yr. Avg.)

1.38588074834271

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 67.65 0.00
Mar 2025 67.78 0.00
Dec 2024 67.81 0.00
Sep 2024 67.97 0.00
Jun 2024 68.04 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROCE of 21.0357666666667% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 37.6941.
  • The company has an efficient Cash Conversion Cycle of -0.266400000000004 days.
  • Company has a healthy liquidity position with current ratio of 6.8953.
  • The company has a good cash flow management; CFO/PAT stands at 1.38588074834271.
  • The company has a high promoter holding of 67.65%.

 Limitations

  • The company has shown a poor profit growth of 9.60844160043988% for the Past 3 years.
  • The company has shown a poor revenue growth of 3.55347191047168% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 61.44 74.69 74.03 58.56 75.61
Total Expenditure 51.2 58.41 58.19 49.85 61.4
Operating Profit 10.24 16.29 15.83 8.71 14.21
Other Income 1.44 1.65 2.32 2.77 2.83
Interest 0.22 0.23 0.26 0.26 0.25
Depreciation 1.07 2.34 2.41 2.31 2.35
Exceptional Items -3.29 0 23.18 -0.21 0
Profit Before Tax 7.11 15.37 38.67 8.71 14.43
Tax 1.78 3.91 6.68 2.13 3.64
Profit After Tax 5.33 11.46 31.99 6.58 10.8
Adjusted EPS (Rs) 0.81 1.73 1.93 0.99 1.62

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 158.57 187.95 217.58 236.71 208.7
Total Expenditure 150.04 168.87 192.56 202.56 185.64
Operating Profit 8.53 19.08 25.03 34.15 23.07
Other Income 2.53 4.39 3.43 5.73 9.28
Interest 0.51 0.51 0.29 0.41 0.81
Depreciation 1.13 1.09 1.53 1.21 1.66
Exceptional Items 0 0 0 -3.46 0
Profit Before Tax 9.41 21.87 26.64 34.81 29.87
Tax 1.54 4.81 7.79 8.09 7.41
Net Profit 7.87 17.06 18.86 26.72 22.46
Adjusted EPS (Rs.) 1.2 2.6 2.88 4.08 3.4

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 13.1 13.1 13.1 13.1 13.22
Total Reserves 97.93 108.83 119.66 145.79 174.18
Borrowings 0 0 0 0 0
Other N/C liabilities 3.09 1.88 4.49 8.49 10.55
Current liabilities 34.57 40.4 34.14 35.18 27.64
Total Liabilities 148.69 164.2 171.4 202.56 225.59
Assets
Net Block 24.44 25.72 22.6 24.28 9.3
Capital WIP 1.9 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 11.39 12.06 28.86 1.12 0
Loans & Advances 14.53 5.66 1.07 0.69 1.72
Other N/C Assets 0.13 0.29 2.62 4.29 23.99
Current Assets 96.31 120.48 116.25 172.17 190.59
Total Assets 148.69 164.2 171.4 202.56 225.59
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 9.41 21.87 26.64 34.81 29.87
Adjustment -0.57 -2.09 -1.4 9.63 8.27
Changes in Assets & Liabilities 4.84 11.59 -11.46 9.5 5.54
Tax Paid -1.8 -3.15 -6.87 -7.28 -8.51
Operating Cash Flow 11.89 28.22 6.91 46.66 35.17
Investing Cash Flow -11.07 -2.26 -25.78 -57.67 -24.55
Financing Cash Flow -1.82 -6.83 -17.55 -0.46 -8.91
Net Cash Flow -1.01 19.13 -36.42 -11.47 1.71

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 68.04 67.97 67.81 67.78 67.65
aresko progressive privat... 20.16 20.14 20.09 20.08 20.05
infinity holdings 25.00 16.66 16.62 16.62 16.58
infinity holdings sidecar... - - - - 17.87
infinity portfolio holdin... - 8.64 8.62 8.61 8.59
rajpal singh kochhar 4.58 4.58 4.57 4.56 4.56
infinity holdings sidecar... 17.97 17.95 17.91 17.90 -
infinity consumer holding... 0.33 - - - -
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 31.96 32.03 32.19 32.22 32.35
authum investment and inf... 1.46 1.46 1.46 1.46 1.46
investor education and pr... 1.55 1.54 1.54 1.54 1.53
lincoln p coelho - 1.17 - 1.17 1.17
manish gupta 2.30 2.39 - 2.49 2.57
mukul mahavir agrawal - 1.75 - 1.74 1.74
sanjiv kumar dudeja - - - - 1.39
sanjiv kumar dudeja - 1.40 - 1.40 -

Annual Reports

Title Link
Title Link
Annual Report 2023
Annual Report 2022
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit ICRA
Credit ICRA
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY25
Concall Q3FY25
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q3FY25
Presentation Q3FY22
Presentation Q2FY25
Presentation Q2FY25
Presentation Q2FY24

Company News

 No Latest News available for this company.Report us

Jagsonpal Pharma Stock Price Analysis and Quick Research Report. Is Jagsonpal Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Jagsonpal Pharma. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Jagsonpal Pharma has a PE ratio of 26.3339504211898 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Jagsonpal Pharma has ROA of 10.4931% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Jagsonpal Pharma has a Current ratio of 6.8953.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Jagsonpal Pharma has a ROE of 14.0194%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Jagsonpal Pharma has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

  • Sales growth: Jagsonpal Pharma has reported revenue growth of -11.8337% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Jagsonpal Pharma for the current financial year is 11.05260131671%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Jagsonpal Pharma is Rs 5 and the yield is 1.0343%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Jagsonpal Pharma is Rs 9.1289. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Jagsonpal Pharma in Ticker for free. Also, one can get the intrinsic value of Jagsonpal Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Jagsonpal Pharma FAQs

Q1. What is Jagsonpal Pharma share price today?
Ans: The current share price of Jagsonpal Pharma is Rs 240.4.

Q2. What is the market capitalisation of Jagsonpal Pharma?
Ans: Jagsonpal Pharma has a market capitalisation of Rs 1601.81534616 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Jagsonpal Pharma?
Ans: The PE ratio of Jagsonpal Pharma is 26.3339504211898 and the P/B ratio of Jagsonpal Pharma is 6.38704312316844, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Jagsonpal Pharma share?
Ans: The 52-week high share price of Jagsonpal Pharma is Rs 328.04, and the 52-week low share price of Jagsonpal Pharma is Rs 153.1.

Q5. Does Jagsonpal Pharma pay dividends?
Ans: Currently, Jagsonpal Pharma pays dividends. Dividend yield of Jagsonpal Pharma is around 1.0343%.

Q6. What are the face value and book value of Jagsonpal Pharma shares?
Ans: The face value of Jagsonpal Pharma shares is Rs 2, while the book value per share of Jagsonpal Pharma is around Rs 37.6387. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Jagsonpal Pharma?
Ans: Jagsonpal Pharma has a total debt of Rs 0 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Jagsonpal Pharma?
Ans: The ROE of Jagsonpal Pharma is 14.0194% and ROCE of Jagsonpal Pharma is 17.7209%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Jagsonpal Pharma a good buy for the long term?
Ans: The Jagsonpal Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Jagsonpal Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Jagsonpal Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Jagsonpal Pharma’s financials?
Ans: You can review Jagsonpal Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Jagsonpal Pharma
X